Deerfield Management Company, L.P. (Series C) Tango Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 1,540,000 shares of TNGX stock, worth $6.28 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
1,540,000
Previous 1,540,000
-0.0%
Holding current value
$6.28 Million
Previous $13.2 Million
10.26%
% of portfolio
0.22%
Previous 0.28%
Shares
2 transactions
Others Institutions Holding TNGX
# of Institutions
123Shares Held
91.7MCall Options Held
3.1KPut Options Held
1.5K-
Trv Gp Iv, LLC Boston, MA16.9MShares$68.8 Million80.09% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA13.3MShares$54.4 Million4.45% of portfolio
-
Boxer Capital, LLC San Diego, CA8.2MShares$33.5 Million3.35% of portfolio
-
Nextech Invest Ag5.53MShares$22.6 Million6.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.02MShares$20.5 Million0.02% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $359M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...